#$%^&*AU2014201239B220160310.pdf#####The present invention provides for a pharmaceutical formulation comprising dapagliflozin propylene glycol hydrate and a pharmaceutical acceptable carrier. Uses of the formulation in the manufacture of a medicament for treating or delaying the progression of Type I or Type 11 diabetes and related conditions are also provided.